Targeted Inactivation of EPS8 using Dendrimer-Mediated Delivery of RNA Interference
We developed polyamidoamine dendrimers conjugated with epidermal growth factor (EGF) for use in receptor-mediated delivery of therapeutics to cancer cells. Here, we demonstrate the utility of this approach to inhibit proliferation and migration of head and neck squamous carcinoma cells through targeting of EPS8, a key regulator of squamous carcinoma growth and motility. Use of EGF-dendrimers to deliver siRNA or shRNA against EPS8 resulted in inhibition of cell growth and reduction in cell motility. Moreover, more profound repression of the target protein was obtained with repeat exposure to the targeting reagent, and was consistent with the altered biological properties. Thus, targeting of EPS8 can be achieved with EGF-conjugated dendrimers delivering EPS8-specific RNAi therapeutics, leading to a reduction in the malignant phenotype of cells.
Q. Yuan et al., "Targeted Inactivation of EPS8 using Dendrimer-Mediated Delivery of RNA Interference," International Journal of Pharmaceutics, vol. 557, pp. 178-181, Elsevier B.V., Feb 2019.
The definitive version is available at https://doi.org/10.1016/j.ijpharm.2018.12.060
Chemical and Biochemical Engineering
Keywords and Phrases
Dendrimer; EGFR; Oral cancer; Signal transduction; Targeted therapy
International Standard Serial Number (ISSN)
Article - Journal
© 2019 Elsevier B.V., All rights reserved.
25 Feb 2019